A roundup of some of the biggest news stories from the pharma industry in China including Aspen's purchase of Sandoz's Chinese business; Moderna's first mRNA facility in China; WuXi Biologics' stock plunge, and BeiGene's USD 1.33 billion CDK2 inhibitor deal…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due…
VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart…
Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
See our Cookie Privacy Policy Here
